Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Long-Term Extension in SLE
NCT03843125Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants With Treatment-Emergent Adverse Events at Week 134, Percentage of Participants With Adverse Events of Special Interest at Week 134 and 3 more. Started Sep 2019; status: terminated.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03843125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843125.